BCG vaccination following latent TB treatment: Possible implications for different settings | Zendy

Lara Goscé | Zendy; Julia Bitencourt | Zendy; Rishi K Gupta | Zendy; Sérgio Arruda | Zendy; Laura C. Rodrigues | Zendy; Ibrahim Abubakar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BCG vaccination following latent TB treatment: Possible implications for different settings

Author(s) -

Lara Goscé,

Julia Bitencourt,

Rishi K Gupta,

Sérgio Arruda,

Laura C. Rodrigues,

Ibrahim Abubakar

Publication year - 2019

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2019.02.026

Subject(s) - latent tuberculosis , medicine , vaccination , tuberculosis , disease , population , bcg vaccine , intensive care medicine , immunology , environmental health , mycobacterium tuberculosis , pathology

Despite much progress globally, TB is still one of the top 10 causes of death worldwide. Several studies have shown the importance of implementing different preventive strategies alongside treatment of TB disease, including BCG vaccination and treatment of latent tuberculosis infection (LTBI). Large-scale population level LTBI treatment is not currently part of WHO guidelines which recommend LTBI treatment only to high risk populations. Moreover, BCG has been widely used in the past decades to both prevent infection with M. tuberculosis and reduce rates of reactivation. In this viewpoint we discuss the hypothesis of BCG vaccination following latent TB treatment and its potential impact across different settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research